Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.
When etoposide-induced activation of pro-caspase-2 is subverted by Z-VDVAD-FMK or stable transfection of pro-caspase-2 antisense, cytochrome c release and other manifestations of apoptosis are attenuated.
OxyHb significantly activated both caspase-2 and caspase-3 in bovine brain microvessel endothelial cells. The irreversible caspase inhibitors Z-VDVAD-FMK (caspse-2 inhibitor) and Z-DEVD-FMK (caspase-3 inhibitor) significantly reduced cell detachment, caspase-2 and -3 activities, DNA ladders, and proteolytic cleavage of PARP2. Activation of caspase-2 and caspase-3 is essential for OxyHb induced apoptosis in endothelial cells, and Z-VDVAD-FMK and Z-DEVD-FMK have the potential to protect cells.
The minimal-length inhibitor of caspase-2, Z-VDVAD-fmk, which also inhibits caspases 3 and 73, prevented doxorubicin-induced nuclear apoptosis, but not cell death4.
1. J. D. Robertson, M. Enoksson et al. Caspase-2 Acts Upstream of Mitochondria to Promote Cytochrome c Release during Etoposide-induced Apoptosis. The Journal of Biological Chemistry. 277, :29803–29809, 2002
2. T. Meguro, B. Chen et al. Caspase Inhibitors Attenuate Oxyhemoglobin-Induced Apoptosis in Endothelial Cells, Stroke. 2001; 32:561-566.
3. Talanian, R. V., Quinlan, C., Trautz, S., Hackett, M. C., Mankovich, J. A., Banach, D., Ghayur, T., Brady, K. D., and Wong, W. W. (1997). Substrate speciﬁcity of caspase family proteases. J. Biol. Chem. 272, 9677–9682.
4. Gamen et al (2000) Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes Dym loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp.Cell Res. 258 223.
|Storage||Store at -20°C|
|Synonyms||Z-VDVAD-fluoromethylketone, Caspase-2 Inhibitor (fluoromethylketone),Z-Val-Asp(OMe)-Val-Ala-Asp(OMe)-FMK|
|Solubility||≥34.8mg/mL in DMSO|
|Chemical Name||methyl (3S)-5-fluoro-3-[[(2S)-2-[[(2S)-2-[[(2S)-4-methoxy-2-[[(2S)-3-methyl-2-(phenylmethoxycarbonylamino)butanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-4-oxopentanoate|
|Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Cell experiment [1,2]:|
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.
25 or 100 μM; 1 or 22 h
Jurkat T-lymphocytes pretreated with 25 μM Z-VDVAD-FMK for 1 h, or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide. According to the MTT-assay, Jurkat cells treated with 100 μM Z-VDVAD-FMK for 22 h prevented doxorubicin-induced nuclear apoptosis, but not cell death.
. J. D. Robertson, M. Enoksson et al. Caspase-2 Acts Upstream of Mitochondria to Promote Cytochrome c Release during Etoposide-induced Apoptosis. The Journal of Biological Chemistry. 277, :29803–29809, 2002.
. Gamen et al (2000) Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes Dym loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp.Cell Res. 258 223.
|Irreversible caspase-2 inhibitor. Attenuates oxyhemoglobin-induced cleavage of PARP and apoptosis in endothelial cells.|
Quality Control & MSDS
- View current batch:
Purity = 98.00%
- COA (Certificate Of Analysis)
- MS (Mass Spectrometry)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
The effect of Z-VDVAD-FMK, a caspase-2 inhibitor, on lipid profile was evaluated by NR staining.